May 2nd 2024
Acalabrutinib plus bendamustine and rituximab bettered progression-free survival over bendamustine and rituximab alone in patients with untreated mantle cell lymphoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Six Idelalisib Studies Halted by FDA
March 15th 2016Six ongoing clinical trials investigating several idelalisib (Zydelig) combinations have been halted due to reports of increased adverse events such as death for patients with hematologic malignancies, according to an alert issued by the FDA.
Read More
Obinutuzumab Approved by the FDA for Follicular Lymphoma
February 27th 2016Obinutuzumab (Gazyva) plus bendamustine, followed by obinutuzumab alone has been approved by the FDA as a treatment of patients with follicular lymphoma who were not responsive to a rituximab regimen, or who relapsed after rituximab-based therapy.
Read More
Dr. Peter Martin on Alternatives to Aggressive Therapy in Mantle Cell Lymphoma
February 5th 2016Peter Martin, MD, discusses the evolving paradigm of treatment for mantle cell lymphoma. Martin says the evolution of the paradigm currently includes Bruton's tyrosine kinase inhibitor, phosphoinositide 3-kinase inhibitor, immunomodulatory treatments, and immunotherapies.
Watch
Dr. John McCarty on Advice for Patients With Lymphoma Seeking Stem Cell Mobilization
January 22nd 2016​John McCarty, MD, medical director, Bone Marrow Transplant Program, Virginia Commonwealth University Health, discusses advice physicians can give to patients with lymphoma seeking stem cell mobilization.
Watch
Patrick Johnston, MD, PhD, assistant professor of medicine, Mayo Clinic, discusses a phase I study that incorporated belinostat with standard CHOP chemotherapy for patients with newly diagnosed peripheral T-cell lymphoma. Johnston says the goal of the trial was to discover the maximum tolerable dose. He said there were no additional significant toxicities in patients and the combination was well-tolerated.
Watch
Dr. Kathryn Kolibaba on R-CHOP and Bortezomib Combo in Diffuse Large B-Cell Lymphoma
January 6th 2016Kathryn Kolibaba, MD, discusses results from the phase II trial dubbed Pyramid Trial. The open-label trial examined a combination of R-CHOP and bortezomib in patients with untreated non-germinal center B-cell-like subtype diffuse large cell lymphoma.
Watch
Response Rates Hover Around 100% for CAR T-cell Therapies in ALL
December 8th 2015Two CD19-targeted chimeric antigen receptor (CAR)-modified T-cell therapies showed complete response (CR) rates from 90% to 100% in patients with high-risk acute lymphoblastic leukemia (ALL), according to data from two studies presented during the 2015 ASH Annual Meeting.
Read More
CAR T-Cell Therapies Produce High Response Rates in Non-Hodgkin Lymphoma
December 8th 2015Updated data shows chimeric antigen receptor (CAR)-modified T-cell therapies continue to remain effective for patients with non-Hodgkin lymphoma (NHL), according to findings presented at the 2015 ASH Annual Meeting.
Read More
Dr. John Leonard on Top Lymphoma Studies at the 2015 ASH Annual Meeting
December 6th 2015Leonard says some of the more interesting studies to crop up in the field of Hodgkin's lymphoma include ones that utilize checkpoint inhibitors, as well as one of the first combination immunotherapies to be used in the disease
Watch
Precision Medicine in Mantle Cell Lymphoma-Balancing Logic With Enthusiasm
October 8th 2015When John P. Leonard, MD, spoke at the American Society of Hematology inaugural meeting on Hematologic Malignancies about mantle cell lymphoma (MCL), he balanced his enthusiasm about the emerging benefits that tumor profiling brings to this disease with an acknowledgement that many important questions about mantle cell lymphoma remain unanswered.
Read More
Two Doses of Polatuzumab Vedotin in Patients With Relapsed/Refractory Follicular Lymphoma
June 11th 2015Catherine M. Diefenbach, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses the efficacy of two doses of polatuzumab vedotin (POV) in patients with relapsed/refractory (RR) follicular lymphoma (FL).
Watch
Duvelisib Shows Encouraging Activity in Lymphoma
April 9th 2015Duvelisib (IPI-145) is an orally administered, dual inhibitor of phosphoinositide 3-kinase (PI3K) delta (δ) and gamma (γ) isoforms, and the drug is selective for PI3K class I isoforms over other lipid and protein kinases.
Read More
New Treatments for Hodgkin Lymphoma Coming to Clinics
March 17th 2015Although treatments and cure rates have increased significantly over the past 60 years for patients with HL, it is crucial that practitioners stay up-to-date on research that can affect outcomes for their patients with this uncommon form of cancer.
Read More
Winter Hematology Meeting Highlighted by Talks on Immunotherapy, Personalized Medicine
February 21st 2015Experts on hematologic malignancies will convene for the 19th Annual International Congress on Hematologic Malignancies, from February 20-21 in Miami, Florida, to provide insight into recent developments in the treatment of the diseases.
Read More